On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies

Clinical Immunology

Volumn 140, Issue 2, 2011, Pages 152-159

  Dellabona, Paolo ^a   Casorati, Giulia ^a   de Lalla, Claudia ^a   Montagna, Daniela ^b   Locatelli, Franco ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

CD1d; Immunotherapy; Leukemia; NKT cells; Transplantation

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CD40 LIGAND; CYCLOPHOSPHAMIDE; FAS LIGAND; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIPID; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HIGH RISK PATIENT; HLA TYPING; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INFECTION SENSITIVITY; INNATE IMMUNITY; INVARIANT NATURAL KILLER T CELL; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA RELAPSE; NATURAL KILLER T CELL; NONHUMAN; ORGAN DONOR; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SUICIDE GENE THERAPY; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

BLOOD DONORS; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; NATURAL KILLER T-CELLS; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 79960464272     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.11.015     Document Type: Review

References (76)

1. Barrett A.J., Horowitz M.M., Pollock B.H., et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N. Engl. J. Med. 1994, 331(19):1253-1258.
2. Lang P., Handgretinger R., Niethammer D., et al. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood 2003, 101(4):1630-1636.
3. Locatelli F., Nollke P., Zecca M., et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 2005, 105(1):410-419.
4. Appelbaum F.R. Haematopoietic cell transplantation as immunotherapy. Nature 2001, 411(6835):385-389.
5. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75(3):555-562.
6. Spierings E., Wieles B., Goulmy E. Minor histocompatibility antigens--big in tumour therapy. Trends Immunol. 2004, 25(2):56-60.
7. Novellino L., Castelli C., Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 2005, 54(3):187-207.
8. Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J. 2004, 10(1):1-7.
9. O'Reilly R.J., Dao T., Koehne G., Scheinberg D., Doubrovina E. Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Semin. Immunol. 2010, 22(3):162-172.
10. Vago L., Perna S.K., Zanussi M., et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N. Engl. J. Med. 2009, 361(5):478-488.
11. Goulmy E. Human minor histocompatibility antigens. Curr. Opin. Immunol. 1996, 8(1):75-81.
12. Roopenian D., Choi E.Y., Brown A. The immunogenomics of minor histocompatibility antigens. Immunol. Rev. 2002, 190:86-94.
13. Garcia K.C., Tallquist M.D., Pease L.R., et al. Alphabeta T cell receptor interactions with syngeneic and allogeneic ligands: affinity measurements and crystallization. Proc. Natl Acad. Sci. USA 1997, 94(25):13838-13843.
14. Deng L., Mariuzza R.A. Recognition of self-peptide-MHC complexes by autoimmune T-cell receptors. Trends Biochem. Sci. 2007, 32(11):500-508.
15. Simpson E., Scott D., James E., Lombardi G., Cwynarski K., Dazzi F., Millrain M., Dyson P.J. Minor H antigens: genes and peptides. Transpl. Immunol. 2002, 10(2-3):115-123.
16. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 1998, 339(17):1186-1193.
17. Comoli P., Basso S., Zecca M., et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am. J. Transplant. 2007, 7(6):1648-1655.
18. Ciceri F., Labopin M., Aversa F., et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008, 112(9):3574-3581.
19. Lang P., Handgretinger R. Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant. 2008, 42(Suppl 2):S54-S59.
20. Fry T.J., Mackall C.L. Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transplant. 2005, 35(Suppl 1):S53-S57.
21. Storek J., Witherspoon R.P., Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant. 1995, 16(3):413-425.
22. Velardi A., Ruggeri L., Mancusi A., Aversa F., Christiansen F.T. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr. Opin. Immunol. 2009, 21(5):525-530.
23. Locatelli F., Pende D., Maccario R., Mingari M.C., Moretta A., Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin. Immunol. 2009, 133(2):171-178.
24. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76(12):2462-2465.
25. Lupo-Stanghellini M.T., Provasi E., Bondanza A., Ciceri F., Bordignon C., Bonini C. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum. Gene Ther. 2010, 21(3):241-250.
26. Ciceri F., Bonini C., Stanghellini M.T., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009, 10(5):489-500.
27. Luznik L., Fuchs E.J. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol. Res. 2010, 47(1-3):65-77.
28. Luznik L., Bolanos-Meade J., Zahurak M., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010, 115(16):3224-3230.
29. Montagna D., Maccario R., Montini E., et al. Anti-leukaemia CTL infusion for treatment of leukaemia relapse in children given allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2007, 39:S54-S55.
30. Montagna D., Maccario R., Locatelli F. Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic stem cell transplantation. Int. J. Immunogenet. 2008, 35(4-5):389-393.
31. Vago L., Forno B., Sormani M.P., et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008, 112(8):3488-3499.
32. Pende D., Marcenaro S., Falco M., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113(13):3119-3129.
33. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15(2):433-444.
34. Kaneko S., Mastaglio S., Bondanza A., et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009, 113(5):1006-1015.
35. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 2007, 25:297-336.
36. Gumperz J.E., Miyake S., Yamamura T., Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 2002, 195(5):625-636.
37. Lee P.T., Benlagha K., Teyton L., Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J. Exp. Med. 2002, 195(5):637-641.
38. Godfrey D.I., Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 2004, 114(10):1379-1388.
39. Terabe M., Berzofsky J.A. The role of NKT cells in tumor immunity. Adv. Cancer Res. 2008, 101:277-348.
40. Morris E.S., MacDonald K.P., Rowe V., et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J. Clin. Invest. 2005, 115(11):3093-3103.
41. Renukaradhya G.J., Khan M.A., Vieira M., Du W., Gervay-Hague J., Brutkiewicz R.R. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 2008, 111(12):5637-5645.
42. Swann J.B., Uldrich A.P., van Dommelen S., Sharkey J., Murray W.K., Godfrey D.I., Smyth M.J. Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 2009, 113(25):6382-6385.
43. Bellone M., Ceccon M., Grioni M., et al. iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS ONE 2010, 5(1):e8646.
44. Tahir S.M., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., Wilson S.B., Balk S.P., Exley M.A. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 2001, 167(7):4046-4050.
45. Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fujii S., Dhodapkar K.M., Krasovsky J. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 2003, 197(12):1667-1676.
46. Molling J.W., Moreno M., van der Vliet H.J., van den Eertwegh A.J., Scheper R.J., von Blomberg B.M., Bontkes H.J. Invariant natural killer T cells and immunotherapy of cancer. Clin. Immunol. 2008, 129(2):182-194.
47. Song L., Asgharzadeh S., Salo J., et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Invest. 2009, 119(6):1524-1536.
48. Hayakawa Y., Takeda K., Yagita H., Smyth M.J., Van Kaer L., Okumura K., Saiki I. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 2002, 100(5):1728-1733.
49. M. Taniguchi, T. Tashiro, N. Dashtsoodol, N. Hongo, H. Watarai. The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int. Immunol. 22 (1) (2010) 1-6.
50. Kohrt H.E., Pillai A.B., Lowsky R., Strober S. NKT cells, Treg, and their interactions in bone marrow transplantation. Eur. J. Immunol. 2010, 40(7):1862-1869.
51. Hashimoto D., Asakura S., Miyake S., Yamamura T., Van Kaer L., Liu C., Tanimoto M., Teshima T. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J. Immunol. 2005, 174(1):551-556.
52. Pillai A.B., George T.I., Dutt S., Strober S. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 2009, 113(18):4458-4467.
53. Godfrey D.I., Stankovic S., Baxter A.G. Raising the NKT cell family. Nat. Immunol. 2010, 11(3):197-206.
54. Kronenberg M., Kinjo Y. Innate-like recognition of microbes by invariant natural killer T cells. Curr. Opin. Immunol. 2009, 21(4):391-396.
55. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant. 2008, 41(5):473-481.
56. Kotsianidis I., Silk J.D., Spanoudakis E., et al. Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood 2006, 107(8):3138-3144.
57. Brigl M., Brenner M.B. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 2004, 22:817-890.
58. Metelitsa L.S., Weinberg K.I., Emanuel P.D., Seeger R.C. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003, 17(6):1068-1077.
59. Fais F., Morabito F., Stelitano C., et al. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int. J. Cancer 2004, 109(3):402-411.
60. Fais F., Tenca C., Cimino G., et al. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia 2005, 19(4):551-556.
61. C. Xu, R. de Vries, L. Visser, A. Diepstra, S.D. Gadola, S. Poppema, A. van den Berg. Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma. Am. J. Hematol. 85 (7) (2010) 539-41.
62. Porcelli S.A., Segelke B.W., Sugita M., Wilson I.A., Brenner M.B. The CD1 family of lipid antigen-presenting molecules. Immunol. Today 1998, 19(8):362-368.
63. Han M., Hannick L.I., DiBrino M., Robinson M.A. Polymorphism of human CD1 genes. Tissue Antigens 1999, 54(2):122-127.
64. Zimmer M.I., Nguyen H.P., Wang B., et al. Polymorphisms in CD1d affect antigen presentation and the activation of CD1d-restricted T cells. Proc. Natl Acad. Sci. USA 2009, 106(6):1909-1914.
65. De Lalla C., Rinaldi A., Montagna D., et al. iNKT cell reconstitution in paediatric leukaemia patients following haploidentical stem cell transplantation suggests contribution to leukaemia control and reveals independent CD4+and CD4-subset maturation programmes. Bone Marrow Transplant. 2010, 45:S206-S.
66. Molling J.W., Langius J.A., Langendijk J.A., et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 2007, 25(7):862-868.
67. Dellabona P., Padovan E., Casorati G., Brockhaus M., Lanzavecchia A. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J. Exp. Med. 1994, 180(3):1171-1176.
68. Exley M.A., Hou R., Shaulov A., et al. Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur. J. Immunol. 2008, 38(6):1756-1766.
69. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.R., Koezuka Y., Kronenberg M. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 2000, 192(5):741-754.
70. Benlagha K., Weiss A., Beavis A., Teyton L., Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 2000, 191(11):1895-1903.
71. Harada Y., Imataki O., Heike Y., et al. Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials. J. Immunother. 2005, 28(4):314-321.
72. Okada H., Nagamura-Inoue T., Mori Y., Takahashi T.A. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes. Eur. J. Immunol. 2006, 36(1):236-244.
73. van der Vliet H.J., Nishi N., Koezuka Y., et al. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J. Immunol. Methods 2001, 247(1-2):61-72.
74. Lin H., Nieda M., Nicol A.J. Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines. Eur. J. Immunol. 2004, 34(10):2664-2671.
75. Crowe N.Y., Coquet J.M., Berzins S.P., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 2005, 202(9):1279-1288.
76. Tupin E., Kinjo Y., Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol. 2007, 5(6):405-417.